Sanft named Chief Patient Experience Officer at Smilow Cancer Hospital
Tara Sanft, M.D., associate professor of Medicine (Medical Oncology) and Director of the Smilow Cancer Hospital (SCH) Survivorship Clinic, has been appointed the inaugural Chief Patient Experience Officer at Yale Cancer Center (YCC) and SCH at Yale New Haven Hospital.
Cancer Center Receives Two-pronged Gift
Christine Moog and Benoit Helluy are supporting the new Yale Center for Immuno-Oncology and Yale Cancer Center’s art therapy program. They see their gift as a way both to propel the science in an area where exciting new cancer treatments appear ready to emerge, and to make battling cancer a less-stressful challenge for patients and their loved ones.Source: Medicine@Yale
Doctors asking how much post-surgical follow-up is needed
On Saturday, Reisman, 52, a former New York lawyer who now freelances for the Shoreline Times, held a party to celebrate two decades of survival. Looking back on the years after her surgery, Reisman said the fear that the cancer could return was compounded by the anxiety she felt about the multiple MRIs she was required to undergo to make sure it hadn’t. Reisman’s experience has buttressed the concern of Dr. Cary Gross, her brother-in-law, a professor of medicine and epidemiology at the Yale School of Medicine. With new studies showing that multiple surveillance procedures don’t necessarily improve patient outcomes in at least some cancers, he is concerned about whether aggressive post-treatment testing is really necessary, given the anxiety, cost and even occasional false positive results that accompany it.Source: New Haven Register
Could Better Predictions Improve End-of-Life Care?
A team of Yale researchers has developed a statistical tool that can improve predictions of whether patients with advanced cancer are likely to die in the near term. Their analysis suggests that better understanding of the end of life could promote patient welfare by transferring more people from aggressive interventions to hospice care.Source: Yale Insights
Inspiring patient gives new meaning to the term “medical history”
Every three weeks, Ola Ferla spends a couple hours in the Smilow Cancer Hospital Apheresis unit, getting treated for a type of lymphoma. While physicians ask her questions, nurses and other staff buzz around her, taking vital signs, placing IVs and connecting Ferla to the machine that removes and treats her blood, then reintroduces it into her body. Ferla is unfazed by any of this, perhaps because she used to be a nurse – during World War II.
Art therapy: helping families cope with cancer
A new art therapy program at Yale Medicine Cancer Center is designed to help patients and their loved ones bond as well as to cope with fear and grief. Using a variety of tools and media, including pencils, pastels, markers, acrylic paint, collage and clay, the art therapist, Elizabeth Ferguson, helps patients and their families express strong feelings.Source: Yale Medicine
Single mom of six battling second round of aggressive cancer
A single mom of six is fighting back from devastating news that her aggressive form of cancer is back. The New Haven mother has triple negative breast cancer. Cheryl Speller was in disbelief after hearing her breast cancer was back.Source: WTNH News Channel 8
Death With Dignity Why is dying at home more the exception than the rule?
The government is coming closer to paying physicians for discussions of end-of-life care planning with patients and families, but even when such plans are in place, actual treatment may take a different and often more aggressive course than the previously agreed-to plans.Source: MedPage Today
New tool helps identify lung cancer patients who will respond to immune therapies
A Yale-led team of researchers has developed a new assay, or investigative tool, to measure the anti-tumor immune activity in non-small cell lung cancer tumors that could lead to a more accurate determination of which patients will respond to immune therapy drugs. Findings from the study were published in the Journal of the National Cancer Institute.